Developers advancing a new slate of weight loss drugs
The Wall Street Journal reviews the slate of mid-stage therapies in clinical trials for obesity. While the market for new therapies is huge, the challenges involved in developing a therapy that's safe, effective and free of embarrassing side effects have been vexing for the R&D crowd.
Among the most promising therapies in the pipeline: Novo Nordisk's liraglutide, which triggered weight loss of more than 5 percent in 75 percent of Phase II volunteers; Amylin Pharmaceuticals' combo of pramlintide and metreleptin, which triggered an average weight loss of 12.7 percent in 177 Phase II volunteers; and Arena Pharmaceuticals' lorcaserin, which is going into Phase III.
- read the article from the Wall Street Journal
Related Articles:
Biotechs discuss obesity therapies at BIO
Obesity drugs pose weighty problems for researchers
Fat cell research points to new approach on obesity
Be the first to comment
More stories about Arena Pharmaceuticals Amylin pharmaceuticals Novo Nordisk Liraglutide lorcaserin obesity
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
